ClinicalTrials.gg
CompletedNCT05841238Updated Jul 10, 2026Results posted

A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants

A Phase 1 interventional study of LY3502970 in Healthy and Obese, sponsored by Eli Lilly and Company. Completed at 3 sites in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-10.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing orforglipron in Obesity — 4 open to participants now, 10 under way, 9 of them phase 3. orforglipron · Obesity.

Enrollment
20th of 22
52 · median 324
Started
2023
with 5 others
Phase 1
6 of 22
none open now
Registered
4th of 22
by date
Lead sponsor
21 of 22
Eli Lilly and Company

Among the 22 studies testing orforglipron in Obesity, this one is the 20th largest by enrollment, is one of 6 that started in 2023, is one of 6 in phase 1, and was the 4th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

4 of the 22 studies testing orforglipron in Obesity are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About orforglipron

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing orforglipron in Obesity, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate how much LY3502970 gets into the bloodstream and how long it takes the body to eliminate when administered orally as tablet and capsule formulations along with effect of food on LY3502970 in healthy overweight and obese participants. The study will also evaluate the safety and tolerability of LY3502970 in these participants. The study is conducted in two parts (part A and B) and will last up to 135 days including the screening period.

03

Conditions studied

  • Healthy
  • Obese

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants who are overtly healthy as determined by medical evaluation
  • Participants with (BMI) of 27.0 kilograms per meter squared (kg/m²) or more
  • Participants with a stable body weight, with 5% or less body weight gain or loss

Exclusion criteria

Exclusion Criteria:

  • Have any type of diabetes with (HbA1c) level of 6.5% or greater or a fasting blood sugar over 120 milligram per deciliter (mg/dL)
  • Obesity induced by other endocrine disorders, such as Cushing's syndrome or Prader-Willi syndrome
  • Have known gastric emptying abnormality
  • Have undergone bariatric surgery (for example: Lap-Band, Gastric Bypass)
  • Known self or family history (first-degree relative) of multiple endocrine neoplasia type 2A or type 2B, thyroid C-cell hyperplasia, or any form of thyroid cancer
  • Have significant previous or current history of comorbidities capable of significantly altering the absorption, metabolism, or elimination of drug
  • Have significant history of or currently have Major Depressive Disorder or psychiatric disorder within the last 2 years
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    Part A: LY3502970 (Periods 1 to 11)

    Participants received a once daily (QD) oral dose of LY3502970 in the tablet or capsule formulation, depending on the period of the study, throughout Periods 1 to 11 as follows: * Period 1 (Day 1-7): 0.8 milligram (mg) LY3502970 tablet (fasted state) * Period 2 (Day 8-14): 2 mg LY3502970 capsule (fasted state) * Period 3 (Day 15-21): 2.5 mg LY3502970 tablet (fasted state) * Period 4 (Day 22-28): 5 mg LY3502970 tablet (fasted state) * Period 5 (Day 29-35): 8 mg LY3502970 capsule (fasted state) * Period 6 (Day 36-42): 10 mg LY3502970 tablet (fasted state) * Period 7 (Day 43-49): 16 mg LY3502970 capsule (fasted state) * Period 8 (Day 50-56): 20 mg LY3502970 tablet (fasted state) * Period 9 (Day 57-63): 36 mg LY3502970 capsule (fasted state) * Period 10 (Day 64-70): 36 mg LY3502970 capsule or 37.5 mg LY3502970 tablet (fed state) * Period 11 (Day 71-77): 37.5 mg LY3502970 tablet (fasted state)

    Drug: LY3502970

  • Experimental
    Part B: 45 mg LY3502970 / 60 mg LY3502970 (Periods 12 to 13)

    Participants after completion of Part A (Periods 1-11), in Part B received a QD oral dose of LY3502970 as follows: * Period 12 (Day 78-84): 45 mg LY3502970 tablet (fasted state) * Period 13 (Day 85-91): 60 mg LY3502970 tablet (fasted state)

    Drug: LY3502970

  • Experimental
    Part B: 35 mg LY3502970 / 35 mg LY3502970 (Periods 12 to 13)

    Participants after completion of Part A (Periods 1-11), in Part B received a QD oral dose of LY3502970 as follows: * Period 12 (Day 78-84): 35 mg LY3502970 tablet (fasted state) * Period 13 (Day 85-91): 35 mg LY3502970 tablet (fasted state)

    Drug: LY3502970

  • Experimental
    Part B: 36 mg LY3502970 DF / 36 mg LY3502970 EPB (Periods 12 to 13)

    Participants after completion of Part A (Periods 1-11), in Part B received a QD oral dose of LY3502970 as follows: * Period 12 (Day 78-84): 36 mg LY3502970 dual-fill (DF) capsule (fasted state) * Period 13 (Day 85-91): 36 mg LY3502970 extemporaneously prepared blended (EPB) capsule (fasted state)

    Drug: LY3502970

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to the 24 Hour Time Point (AUC[0-24]) of LY3502970 in Fasted State - Part A: Periods 1-9, 11 and Part B: Periods 12-13

    PK: AUC\[0-24\] of LY3502970 in fasted state

    Time frame: Predose and 0.5, 1, 2, 4, 6, 8, 12, 16, 20, and 24 hours post-dose on Day 7 of each treatment period in Part A: Periods 1-9, 11 and Part B: Periods 12-13

  2. PK: Maximum Observed Concentration (Cmax) of LY3502970 in Fasted State - Part A: Periods 1-9, 11 and Part B: Periods 12-13

    PK: Cmax of LY3502970 in fasted state

    Time frame: Predose and 0.5, 1, 2, 4, 6, 8, 12, 16, 20, and 24 hours post-dose on Day 7 of each treatment period in Part A: Periods 1-9, 11 and Part B: Periods 12-13

  3. PK: Time to Maximum Observed Concentration (Tmax) of LY3502970 in Fasted State - Part A: Periods 1-9, 11 and Part B: Periods 12-13

    PK: Tmax of LY3502970 in fasted state

    Time frame: Predose and 0.5, 1, 2, 4, 6, 8, 12, 16, 20, and 24 hours post-dose on Day 7 of each treatment period in Part A: Periods 1-9, 11 and Part B: Periods 12-13

Secondary outcomes

  1. PK: Area Under the Concentration Versus Time Curve From Time Zero to the 24 Hour Time Point (AUC[0-24]) of LY3502970 in Fed State - Part A: Period 10

    PK: AUC\[0-24\] of LY3502970 in fed state

    Time frame: Predose and 0.5, 1, 2, 4, 6, 8, 12, 16, 20, and 24 hours post-dose on Day 7 of Part A: Period 10 (Day 70)

  2. PK: Maximum Observed Concentration (Cmax) of LY3502970 in Fed State - Part A: Period 10

    PK: Cmax of LY3502970 in fed state

    Time frame: Predose and 0.5, 1, 2, 4, 6, 8, 12, 16, 20, and 24 hours post-dose on Day 7 of Part A: Period 10 (Day 70)

  3. PK: Time to Maximum Observed Concentration (Tmax) of LY3502970 in Fed State - Part A: Period 10

    PK: Tmax of LY3502970 in fed state

    Time frame: Predose and 0.5, 1, 2, 4, 6, 8, 12, 16, 20, and 24 hours post-dose on Day 7 of Part A: Period 10 (Day 70)

07

Results

Posted Jul 10, 2026

Participant flow

The study had two sequential parts ; Part A and Part B. Part A consisted of dosing periods 1 to 11 and Part B consisted of dosing periods 12 and 13. Participants enrolled in the study, began in Part A, and continued into Part B.

Period 1
Participant flow — Period 1
MilestonePart A: LY3502970 (Periods 1 to 11)Part B: 35 mg LY3502970 / 35 mg LY3502970 (Periods 12 to 13)Part B: 45 mg LY3502970 / 60 mg LY3502970 (Periods 12 to 13)Part B: 36 mg LY3502970 DF / 36 mg LY3502970 EPB (Periods 12 to 13)
Started52000
Completed50000
Not completed2000
Withdrew: Withdrawal by subject2000
Period 2 to Period 3
Participant flow — Period 2 to Period 3
MilestonePart A: LY3502970 (Periods 1 to 11)Part B: 35 mg LY3502970 / 35 mg LY3502970 (Periods 12 to 13)Part B: 45 mg LY3502970 / 60 mg LY3502970 (Periods 12 to 13)Part B: 36 mg LY3502970 DF / 36 mg LY3502970 EPB (Periods 12 to 13)
Started50000
Completed50000
Not completed0000
Period 4
Participant flow — Period 4
MilestonePart A: LY3502970 (Periods 1 to 11)Part B: 35 mg LY3502970 / 35 mg LY3502970 (Periods 12 to 13)Part B: 45 mg LY3502970 / 60 mg LY3502970 (Periods 12 to 13)Part B: 36 mg LY3502970 DF / 36 mg LY3502970 EPB (Periods 12 to 13)
Started50000
Completed49000
Not completed1000
Withdrew: Adverse event1000
Period 5
Participant flow — Period 5
MilestonePart A: LY3502970 (Periods 1 to 11)Part B: 35 mg LY3502970 / 35 mg LY3502970 (Periods 12 to 13)Part B: 45 mg LY3502970 / 60 mg LY3502970 (Periods 12 to 13)Part B: 36 mg LY3502970 DF / 36 mg LY3502970 EPB (Periods 12 to 13)
Started49000
Completed49000
Not completed0000
Period 6
Participant flow — Period 6
MilestonePart A: LY3502970 (Periods 1 to 11)Part B: 35 mg LY3502970 / 35 mg LY3502970 (Periods 12 to 13)Part B: 45 mg LY3502970 / 60 mg LY3502970 (Periods 12 to 13)Part B: 36 mg LY3502970 DF / 36 mg LY3502970 EPB (Periods 12 to 13)
Started49000
Completed46000
Not completed3000
Withdrew: Physician decision1000
Withdrew: Use of prohibited concomitant medication1000
Withdrew: Non-compliance with study requirements1000
Period 7
Participant flow — Period 7
MilestonePart A: LY3502970 (Periods 1 to 11)Part B: 35 mg LY3502970 / 35 mg LY3502970 (Periods 12 to 13)Part B: 45 mg LY3502970 / 60 mg LY3502970 (Periods 12 to 13)Part B: 36 mg LY3502970 DF / 36 mg LY3502970 EPB (Periods 12 to 13)
Started46000
Completed46000
Not completed0000
Period 8
Participant flow — Period 8
MilestonePart A: LY3502970 (Periods 1 to 11)Part B: 35 mg LY3502970 / 35 mg LY3502970 (Periods 12 to 13)Part B: 45 mg LY3502970 / 60 mg LY3502970 (Periods 12 to 13)Part B: 36 mg LY3502970 DF / 36 mg LY3502970 EPB (Periods 12 to 13)
Started46000
Completed45000
Not completed1000
Withdrew: Adverse event1000
Period 9
Participant flow — Period 9
MilestonePart A: LY3502970 (Periods 1 to 11)Part B: 35 mg LY3502970 / 35 mg LY3502970 (Periods 12 to 13)Part B: 45 mg LY3502970 / 60 mg LY3502970 (Periods 12 to 13)Part B: 36 mg LY3502970 DF / 36 mg LY3502970 EPB (Periods 12 to 13)
Started45000
Completed42000
Not completed3000
Withdrew: Adverse event3000
Period 10: 36 mg LY3502970 Capsule
Participant flow — Period 10: 36 mg LY3502970 Capsule
MilestonePart A: LY3502970 (Periods 1 to 11)Part B: 35 mg LY3502970 / 35 mg LY3502970 (Periods 12 to 13)Part B: 45 mg LY3502970 / 60 mg LY3502970 (Periods 12 to 13)Part B: 36 mg LY3502970 DF / 36 mg LY3502970 EPB (Periods 12 to 13)
Started21000
Completed20000
Not completed1000
Withdrew: Protocol deviation1000
Period 10: 37.5 mg LY3502970 Tablet
Participant flow — Period 10: 37.5 mg LY3502970 Tablet
MilestonePart A: LY3502970 (Periods 1 to 11)Part B: 35 mg LY3502970 / 35 mg LY3502970 (Periods 12 to 13)Part B: 45 mg LY3502970 / 60 mg LY3502970 (Periods 12 to 13)Part B: 36 mg LY3502970 DF / 36 mg LY3502970 EPB (Periods 12 to 13)
Started21000
Completed21000
Not completed0000
Period 11
Participant flow — Period 11
MilestonePart A: LY3502970 (Periods 1 to 11)Part B: 35 mg LY3502970 / 35 mg LY3502970 (Periods 12 to 13)Part B: 45 mg LY3502970 / 60 mg LY3502970 (Periods 12 to 13)Part B: 36 mg LY3502970 DF / 36 mg LY3502970 EPB (Periods 12 to 13)
Started41000
Completed40000
Not completed1000
Withdrew: Adverse event1000
Periods 12 to 13
Participant flow — Periods 12 to 13
MilestonePart A: LY3502970 (Periods 1 to 11)Part B: 35 mg LY3502970 / 35 mg LY3502970 (Periods 12 to 13)Part B: 45 mg LY3502970 / 60 mg LY3502970 (Periods 12 to 13)Part B: 36 mg LY3502970 DF / 36 mg LY3502970 EPB (Periods 12 to 13)
Started072112
Completed072112
Not completed0000

Outcome measures

PrimaryPharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to the 24 Hour Time Point (AUC[0-24]) of LY3502970 in Fasted State - Part A: Periods 1-9, 11 and Part B: Periods 12-13

PK: AUC\[0-24\] of LY3502970 in fasted state

Time frame:
Predose and 0.5, 1, 2, 4, 6, 8, 12, 16, 20, and 24 hours post-dose on Day 7 of each treatment period in Part A: Periods 1-9, 11 and Part B: Periods 12-13
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*h/mL)
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to the 24 Hour Time Point (AUC[0-24]) of LY3502970 in Fasted State - Part A: Periods 1-9, 11 and Part B: Periods 12-13
nanogram*hour per milliliter (ng*h/mL)Part A: Period 1 (Day 1-7): 0.8 mg LY3502970 Tablet (Fasted State)Part A: Period 2 (Day 8-14): 2 mg LY3502970 Capsule (Fasted State)Part A: Period 3 (Day 15-21): 2.5 mg LY3502970 Tablet (Fasted State)Part A: Period 4 (Day 22-28): 5 mg LY3502970 Tablet (Fasted State)Part A: Period 5 (Day 29-35): 8 mg LY3502970 Capsule (Fasted State)Part A: Period 6 (Day 36-42): 10 mg LY3502970 Tablet (Fasted State)Part A: Period 7 (Day 43-49): 16 mg LY3502970 Capsule (Fasted State)Part A: Period 8 (Day 50-56): 20 mg LY3502970 Tablet (Fasted State)Part A: Period 9 (Day 57-63): 36 mg LY3502970 Capsule (Fasted State)Part A: Period 11 (Day 71-77): 37.5 mg LY3502970 Tablet (Fasted State)Part B: Period 12 (Day 78-84): 35 mg LY3502970 Tablet (Fasted State)Part B: Period 13 (Day 85-91): 35 mg LY3502970 Tablet (Fasted State)Part B: Period 12 (Day 78-84): 45 mg LY3502970 Tablet (Fasted State)Part B: Period 13 (Day 85-91): 60 mg LY3502970 Tablet (Fasted State)Part B: Period 12 (Day 78-84): 36 mg LY3502970 DF Capsule (Fasted State)Part B: Period 13 (Day 85-91): 36 mg LY3502970 EPB Capsule (Fasted State)
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to the 24 Hour Time Point (AUC[0-24]) of LY3502970 in Fasted State - Part A: Periods 1-9, 11 and Part B: Periods 12-1390.8 ± 27199 ± 34294 ± 31548 ± 29700 ± 421080 ± 321250 ± 401970 ± 481580 ± 723680 ± 473730 ± 374080 ± 404100 ± 516410 ± 491950 ± 593030 ± 45
PrimaryPK: Maximum Observed Concentration (Cmax) of LY3502970 in Fasted State - Part A: Periods 1-9, 11 and Part B: Periods 12-13

PK: Cmax of LY3502970 in fasted state

Time frame:
Predose and 0.5, 1, 2, 4, 6, 8, 12, 16, 20, and 24 hours post-dose on Day 7 of each treatment period in Part A: Periods 1-9, 11 and Part B: Periods 12-13
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
PK: Maximum Observed Concentration (Cmax) of LY3502970 in Fasted State - Part A: Periods 1-9, 11 and Part B: Periods 12-13
nanograms per milliliter (ng/mL)Part A: Period 1 (Day 1-7): 0.8 mg LY3502970 Tablet (Fasted State)Part A: Period 2 (Day 8-14): 2 mg LY3502970 Capsule (Fasted State)Part A: Period 3 (Day 15-21): 2.5 mg LY3502970 Tablet (Fasted State)Part A: Period 4 (Day 22-28): 5 mg LY3502970 Tablet (Fasted State)Part A: Period 5 (Day 29-35): 8 mg LY3502970 Capsule (Fasted State)Part A: Period 6 (Day 36-42): 10 mg LY3502970 Tablet (Fasted State)Part A: Period 7 (Day 43-49): 16 mg LY3502970 Capsule (Fasted State)Part A: Period 8 (Day 50-56): 20 mg LY3502970 Tablet (Fasted State)Part A: Period 9 (Day 57-63): 36 mg LY3502970 Capsule (Fasted State)Part A: Period 11 (Day 71-77): 37.5 mg LY3502970 Tablet (Fasted State)Part B: Period 12 (Day 78-84): 35 mg LY3502970 Tablet (Fasted State)Part B: Period 13 (Day 85-91): 35 mg LY3502970 Tablet (Fasted State)Part B: Period 12 (Day 78-84): 45 mg LY3502970 Tablet (Fasted State)Part B: Period 13 (Day 85-91): 60 mg LY3502970 Tablet (Fasted State)Part B: Period 12 (Day 78-84): 36 mg LY3502970 DF Capsule (Fasted State)Part B: Period 13 (Day 85-91): 36 mg LY3502970 EPB Capsule (Fasted State)
PK: Maximum Observed Concentration (Cmax) of LY3502970 in Fasted State - Part A: Periods 1-9, 11 and Part B: Periods 12-136.08 ± 2613.5 ± 3919.9 ± 3436.6 ± 3545.1 ± 4969.8 ± 3473.5 ± 58126 ± 57100 ± 89257 ± 54234 ± 39295 ± 39275 ± 49460 ± 55109 ± 58203 ± 48
PrimaryPK: Time to Maximum Observed Concentration (Tmax) of LY3502970 in Fasted State - Part A: Periods 1-9, 11 and Part B: Periods 12-13

PK: Tmax of LY3502970 in fasted state

Time frame:
Predose and 0.5, 1, 2, 4, 6, 8, 12, 16, 20, and 24 hours post-dose on Day 7 of each treatment period in Part A: Periods 1-9, 11 and Part B: Periods 12-13
Reported as:
Median · hours
PK: Time to Maximum Observed Concentration (Tmax) of LY3502970 in Fasted State - Part A: Periods 1-9, 11 and Part B: Periods 12-13
hoursPart A: Period 1 (Day 1-7): 0.8 mg LY3502970 Tablet (Fasted State)Part A: Period 2 (Day 8-14): 2 mg LY3502970 Capsule (Fasted State)Part A: Period 3 (Day 15-21): 2.5 mg LY3502970 Tablet (Fasted State)Part A: Period 4 (Day 22-28): 5 mg LY3502970 Tablet (Fasted State)Part A: Period 5 (Day 29-35): 8 mg LY3502970 Capsule (Fasted State)Part A: Period 6 (Day 36-42): 10 mg LY3502970 Tablet (Fasted State)Part A: Period 7 (Day 43-49): 16 mg LY3502970 Capsule (Fasted State)Part A: Period 8 (Day 50-56): 20 mg LY3502970 Tablet (Fasted State)Part A: Period 9 (Day 57-63): 36 mg LY3502970 Capsule (Fasted State)Part A: Period 11 (Day 71-77): 37.5 mg LY3502970 Tablet (Fasted State)Part B: Period 12 (Day 78-84): 35 mg LY3502970 Tablet (Fasted State)Part B: Period 13 (Day 85-91): 35 mg LY3502970 Tablet (Fasted State)Part B: Period 12 (Day 78-84): 45 mg LY3502970 Tablet (Fasted State)Part B: Period 13 (Day 85-91): 60 mg LY3502970 Tablet (Fasted State)Part B: Period 12 (Day 78-84): 36 mg LY3502970 DF Capsule (Fasted State)Part B: Period 13 (Day 85-91): 36 mg LY3502970 EPB Capsule (Fasted State)
PK: Time to Maximum Observed Concentration (Tmax) of LY3502970 in Fasted State - Part A: Periods 1-9, 11 and Part B: Periods 12-136.00 (3.98 to 8.00)6.00 (0.00 to 12.00)6.00 (2.00 to 8.02)6.00 (2.00 to 23.83)8.00 (1.00 to 12.00)6.00 (0.00 to 12.00)6.00 (0.00 to 23.83)8.00 (0.00 to 23.83)8.00 (2.00 to 23.87)6.03 (1.00 to 12.00)8.00 (4.00 to 12.00)4.03 (4.00 to 8.00)4.07 (2.07 to 8.00)8.00 (2.00 to 12.00)5.92 (1.92 to 7.92)6.88 (1.92 to 7.93)
SecondaryPK: Area Under the Concentration Versus Time Curve From Time Zero to the 24 Hour Time Point (AUC[0-24]) of LY3502970 in Fed State - Part A: Period 10

PK: AUC\[0-24\] of LY3502970 in fed state

Time frame:
Predose and 0.5, 1, 2, 4, 6, 8, 12, 16, 20, and 24 hours post-dose on Day 7 of Part A: Period 10 (Day 70)
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*h/mL)
PK: Area Under the Concentration Versus Time Curve From Time Zero to the 24 Hour Time Point (AUC[0-24]) of LY3502970 in Fed State - Part A: Period 10
nanogram*hour per milliliter (ng*h/mL)Part A: Period 10 (Day 64-70): 36 mg LY3502970 Capsule (Fed State)Part A: Period 10 (Day 64-70): 37.5 mg LY3502970 Tablet (Fed State)
PK: Area Under the Concentration Versus Time Curve From Time Zero to the 24 Hour Time Point (AUC[0-24]) of LY3502970 in Fed State - Part A: Period 101230 ± 1393170 ± 36
SecondaryPK: Maximum Observed Concentration (Cmax) of LY3502970 in Fed State - Part A: Period 10

PK: Cmax of LY3502970 in fed state

Time frame:
Predose and 0.5, 1, 2, 4, 6, 8, 12, 16, 20, and 24 hours post-dose on Day 7 of Part A: Period 10 (Day 70)
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
PK: Maximum Observed Concentration (Cmax) of LY3502970 in Fed State - Part A: Period 10
nanograms per milliliter (ng/mL)Part A: Period 10 (Day 64-70): 36 mg LY3502970 Capsule (Fed State)Part A: Period 10 (Day 64-70): 37.5 mg LY3502970 Tablet (Fed State)
PK: Maximum Observed Concentration (Cmax) of LY3502970 in Fed State - Part A: Period 1081.0 ± 104203 ± 51
SecondaryPK: Time to Maximum Observed Concentration (Tmax) of LY3502970 in Fed State - Part A: Period 10

PK: Tmax of LY3502970 in fed state

Time frame:
Predose and 0.5, 1, 2, 4, 6, 8, 12, 16, 20, and 24 hours post-dose on Day 7 of Part A: Period 10 (Day 70)
Reported as:
Median · hours
PK: Time to Maximum Observed Concentration (Tmax) of LY3502970 in Fed State - Part A: Period 10
hoursPart A: Period 10 (Day 64-70): 36 mg LY3502970 Capsule (Fed State)Part A: Period 10 (Day 64-70): 37.5 mg LY3502970 Tablet (Fed State)
PK: Time to Maximum Observed Concentration (Tmax) of LY3502970 in Fed State - Part A: Period 1012.00 (0.00 to 23.83)6.00 (0.00 to 23.83)

Adverse events

Collected over Baseline to end of follow-up (up to 15 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: Period 1 (Day 1-7): 0.8 mg LY3502970 Tablet (Fasted State)0/52 (0%)0/52 (0%)7/52 (13.5%)
Part A: Period 2 (Day 8-14): 2 mg LY3502970 Capsule (Fasted State)0/50 (0%)0/50 (0%)6/50 (12%)
Part A: Period 3 (Day 15-21): 2.5 mg LY3502970 Tablet (Fasted State)0/50 (0%)0/50 (0%)3/50 (6%)
Part A: Period 4 (Day 22-28): 5 mg LY3502970 Tablet (Fasted State)0/50 (0%)0/50 (0%)8/50 (16%)
Part A: Period 5 (Day 29-35): 8 mg LY3502970 Capsule (Fasted State)0/49 (0%)0/49 (0%)13/49 (26.5%)
Part A: Period 6 (Day 36-42): 10 mg LY3502970 Tablet (Fasted State)0/49 (0%)0/49 (0%)9/49 (18.4%)
Part A: Period 7 (Day 43-49): 16 mg LY3502970 Capsule (Fasted State)0/46 (0%)0/46 (0%)4/46 (8.7%)
Part A: Period 8 (Day 50-56): 20 mg LY3502970 Tablet (Fasted State)0/46 (0%)1/46 (2.2%)4/46 (8.7%)
Part A: Period 9 (Day 57-63): 36 mg LY3502970 Capsule (Fasted State)0/45 (0%)1/45 (2.2%)2/45 (4.4%)
Part A: Period 10 (Day 64-70): 36 mg LY3502970 Capsule (Fed State)0/21 (0%)0/21 (0%)3/21 (14.3%)
Part A: Period 10 (Day 64-70): 37.5 mg LY3502970 Tablet (Fed State)0/21 (0%)0/21 (0%)12/21 (57.1%)
Part A: Period 11 (Day 71-77): 37.5 mg LY3502970 Tablet (Fasted State)0/41 (0%)0/41 (0%)12/41 (29.3%)
Part B: Period 12 (Day 78-84): 35 mg LY3502970 Tablet (Fasted State)0/7 (0%)0/7 (0%)3/7 (42.9%)
Part B: Period 13 (Day 85-91): 35 mg LY3502970 Tablet (Fasted State)0/7 (0%)0/7 (0%)1/7 (14.3%)
Part B: Period 12 (Day 78-84): 45 mg LY3502970 Tablet (Fasted State)0/21 (0%)0/21 (0%)4/21 (19%)
Part B: Period 13 (Day 85-91): 60 mg LY3502970 Tablet (Fasted State)0/21 (0%)0/21 (0%)5/21 (23.8%)
Part B: Period 12 (Day 78-84): 36 mg LY3502970 DF Capsule (Fasted State)0/12 (0%)0/12 (0%)3/12 (25%)
Part B: Period 13 (Day 85-91): 36 mg LY3502970 EPB Capsule (Fasted State)0/12 (0%)0/12 (0%)6/12 (50%)
Most frequent serious events
Most frequent serious events
EventPart A: Period 1 (Day 1-7): 0.8 mg LY3502970 Tablet (Fasted State)Part A: Period 2 (Day 8-14): 2 mg LY3502970 Capsule (Fasted State)Part A: Period 3 (Day 15-21): 2.5 mg LY3502970 Tablet (Fasted State)Part A: Period 4 (Day 22-28): 5 mg LY3502970 Tablet (Fasted State)Part A: Period 5 (Day 29-35): 8 mg LY3502970 Capsule (Fasted State)Part A: Period 6 (Day 36-42): 10 mg LY3502970 Tablet (Fasted State)Part A: Period 7 (Day 43-49): 16 mg LY3502970 Capsule (Fasted State)Part A: Period 8 (Day 50-56): 20 mg LY3502970 Tablet (Fasted State)Part A: Period 9 (Day 57-63): 36 mg LY3502970 Capsule (Fasted State)Part A: Period 10 (Day 64-70): 36 mg LY3502970 Capsule (Fed State)Part A: Period 10 (Day 64-70): 37.5 mg LY3502970 Tablet (Fed State)Part A: Period 11 (Day 71-77): 37.5 mg LY3502970 Tablet (Fasted State)Part B: Period 12 (Day 78-84): 35 mg LY3502970 Tablet (Fasted State)Part B: Period 13 (Day 85-91): 35 mg LY3502970 Tablet (Fasted State)Part B: Period 12 (Day 78-84): 45 mg LY3502970 Tablet (Fasted State)Part B: Period 13 (Day 85-91): 60 mg LY3502970 Tablet (Fasted State)Part B: Period 12 (Day 78-84): 36 mg LY3502970 DF Capsule (Fasted State)Part B: Period 13 (Day 85-91): 36 mg LY3502970 EPB Capsule (Fasted State)
Chest painGeneral disorders0/520/500/500/500/490/490/460/461/450/210/210/410/70/70/210/210/120/12
AppendicitisInfections and infestations0/520/500/500/500/490/490/461/460/450/210/210/410/70/70/210/210/120/12
Most frequent other events
Showing 10 of 12
Most frequent other events
EventPart A: Period 1 (Day 1-7): 0.8 mg LY3502970 Tablet (Fasted State)Part A: Period 2 (Day 8-14): 2 mg LY3502970 Capsule (Fasted State)Part A: Period 3 (Day 15-21): 2.5 mg LY3502970 Tablet (Fasted State)Part A: Period 4 (Day 22-28): 5 mg LY3502970 Tablet (Fasted State)Part A: Period 5 (Day 29-35): 8 mg LY3502970 Capsule (Fasted State)Part A: Period 6 (Day 36-42): 10 mg LY3502970 Tablet (Fasted State)Part A: Period 7 (Day 43-49): 16 mg LY3502970 Capsule (Fasted State)Part A: Period 8 (Day 50-56): 20 mg LY3502970 Tablet (Fasted State)Part A: Period 9 (Day 57-63): 36 mg LY3502970 Capsule (Fasted State)Part A: Period 10 (Day 64-70): 36 mg LY3502970 Capsule (Fed State)Part A: Period 10 (Day 64-70): 37.5 mg LY3502970 Tablet (Fed State)Part A: Period 11 (Day 71-77): 37.5 mg LY3502970 Tablet (Fasted State)Part B: Period 12 (Day 78-84): 35 mg LY3502970 Tablet (Fasted State)Part B: Period 13 (Day 85-91): 35 mg LY3502970 Tablet (Fasted State)Part B: Period 12 (Day 78-84): 45 mg LY3502970 Tablet (Fasted State)Part B: Period 13 (Day 85-91): 60 mg LY3502970 Tablet (Fasted State)Part B: Period 12 (Day 78-84): 36 mg LY3502970 DF Capsule (Fasted State)Part B: Period 13 (Day 85-91): 36 mg LY3502970 EPB Capsule (Fasted State)
NauseaGastrointestinal disorders2/520/500/500/501/492/490/461/460/452/214/216/411/70/72/211/211/125/12
HeadacheNervous system disorders2/520/502/506/501/490/490/460/460/450/214/215/410/70/70/211/210/122/12
DyspepsiaGastrointestinal disorders1/520/500/502/505/491/490/462/460/450/212/213/411/70/70/211/210/120/12
FlatulenceGastrointestinal disorders0/520/500/500/500/490/490/460/460/450/210/210/411/70/70/210/210/120/12
VomitingGastrointestinal disorders2/520/500/501/502/490/491/461/460/450/211/215/411/70/71/213/210/121/12
IntertrigoSkin and subcutaneous tissue disorders0/520/500/500/500/490/490/460/460/450/211/210/410/71/70/210/210/120/12
ConstipationGastrointestinal disorders2/525/500/501/502/496/490/460/460/451/212/210/410/70/70/211/211/120/12
Abdominal distensionGastrointestinal disorders0/520/500/500/502/490/490/460/460/450/211/211/410/70/72/210/210/120/12
DiarrhoeaGastrointestinal disorders0/521/500/500/503/490/493/461/462/450/211/211/410/70/70/210/211/121/12
Gastrooesophageal reflux diseaseGastrointestinal disorders0/520/501/500/501/491/490/460/460/450/211/210/410/70/70/210/210/121/12

Baseline characteristics

All enrolled participants (period 1).

Age, Continuous
Age, Continuous(years)Part A: LY3502970 (Periods 1 to 11)
Mean42.3 ± 11.9
Sex: Female, Male
Sex: Female, Male(Participants)Part A: LY3502970 (Periods 1 to 11)
Female23
Male29
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A: LY3502970 (Periods 1 to 11)
Hispanic or Latino20
Not Hispanic or Latino32
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A: LY3502970 (Periods 1 to 11)
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American25
White27
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Part A: LY3502970 (Periods 1 to 11)
United States52
08

Study locations

3 sites
  • LabCorp CRU, Inc.
    Daytona Beach, Florida 32117, United States
  • Labcorp Clinical Research LP
    Dallas, Texas 75247, United States
  • LabCorp CRU, Inc.
    Madison, Wisconsin 53704, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in Sep 2023, 4 months.

Results were first posted in Jul 2026, 2 years 9 months after primary completion.

Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 4 months is below that.

Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2023
First posted
May 3, 2023
StartActual
Apr 26, 2023
Primary completionActual
Sep 14, 2023
CompletionActual
Nov 13, 2023
Results first posted
Jul 10, 2026
Last update
Jul 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05841238
Responsible party
Sponsor
First posted
May 3, 2023
Start date
Apr 26, 2023
Primary completion
Sep 14, 2023
Completion
Nov 13, 2023
Results posted
Jul 10, 2026
Last update
Jul 10, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Orforglipron

Start the discussion